MiNK Therapeutics Inc (INKT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$10.71+6.46%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge MiNK Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	1.02M
EPS	—	-0.51
Annual ending 2026-12-31
Revenue	—	1.9M
EPS	—	-2.205
Annual ending 2027-12-31
Revenue	—	2.75M
EPS	—	-2.19

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advance ARDS Phase 2 and GVHD clinical data in 2026	MiNK is advancing key clinical trials like ARDS Phase 2 in 2026.	Improving	Failure to initiate ARDS Phase 2 or release GVHD data in 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management advanced agenT-797 into a randomized Phase 2 trial in acute lung injury and ARDS in 2026-Q1 and reported initial positive Day 28 observations in 2026-Q2. Net losses were $2.7M in 2026-Q1 and $3.1M in 2026-Q2, with cash declining from $9.5M to $8.8M. The trajectory shows active clinical progression with ongoing data generation and site activations, delivering on stated clinical advancement. Delivery assessment Oct 24, 2026
Reduce net losses toward -$2.74M by 2026-Q1	Net losses improved from -$4.24M to -$2.74M recently.	Under Pressure	Net losses worsen beyond -$2.74M in 2026-Q1	Net income: $-3.128M FY2026-Q2; GAAP. Published target: Net income >= -$2.74M in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 13, 2026-3,128,201 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 7a55205b-77e5-477d-87ec-badbacd7ddbc. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 of last 4 quarters including 2026-Q2, 2026-Q1, and 2025-Q4. Management emphasizes expense discipline and reduced operating burn. Net loss improved from $4.2M in 2025-Q2 to $3.1M in 2026-Q2, and EPS loss improved from $1.76 to $1.20 per share year-over-year for first half. The trajectory shows delivering on cost discipline amid clinical advancement. Delivery assessment Oct 24, 2026
Improve operating income toward -$2.88M by 2026-Q1	A supporting condition in MiNK Therapeutics Inc's published investment case. The stated target is Operating income >= -$2.88M in 2026-Q1.	Intact	Operating income worsens beyond -$2.88M in 2026-Q1	Operating income: $-3.217M FY2026-Q2; GAAP. Published target: Operating income >= -$2.88M in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 13, 2026-3,216,894 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 7a55205b-77e5-477d-87ec-badbacd7ddbc. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 of last 4 quarters including 2026-Q2, 2026-Q1, and 2025-Q4. Management emphasizes expense discipline and reduced operating burn. Net loss improved from $4.2M in 2025-Q2 to $3.1M in 2026-Q2, and EPS loss improved from $1.76 to $1.20 per share year-over-year for first half. The trajectory shows delivering on cost discipline amid clinical advancement. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 2
2026-07-25	Unavailable	Unavailable	2 / 2
2026-07-26	Unavailable	Unavailable	2 / 2
2026-07-27	Unavailable	Unavailable	2 / 2
2026-07-28	Unavailable	Unavailable	2 / 2
2026-07-29	Unavailable	Unavailable	2 / 2
2026-07-30	Unavailable	Unavailable	2 / 2
2026-07-31	Unavailable	Unavailable	2 / 2
2026-08-01	Unavailable	Unavailable	2 / 2
2026-08-02	Unavailable	Unavailable	2 / 2
2026-08-03	Unavailable	Unavailable	2 / 2
2026-08-04	Unavailable	Unavailable	2 / 2
2026-08-05	Unavailable	Unavailable	2 / 2
2026-08-06	Unavailable	Unavailable	2 / 2
2026-08-07	Unavailable	Unavailable	2 / 2
2026-08-08	Unavailable	Unavailable	2 / 2
2026-08-09	Unavailable	Unavailable	2 / 2
2026-08-10	Unavailable	Unavailable	2 / 2
2026-08-12	Unavailable	Unavailable	2 / 2
2026-08-13	Unavailable	Unavailable	2 / 2
2026-08-14	Unavailable	Unavailable	2 / 2
2026-08-15	Unavailable	Unavailable	2 / 2
2026-08-16	Unavailable	Unavailable	2 / 2
2026-08-17	Unavailable	Unavailable	2 / 2
2026-08-18	Unavailable	Unavailable	2 / 2
2026-08-19	Unavailable	Unavailable	2 / 2
2026-08-20	Unavailable	Unavailable	2 / 1
2026-08-21	Unavailable	Unavailable	2 / 1
2026-08-22	Unavailable	Unavailable	2 / 1
2026-08-23	Unavailable	Unavailable	2 / 1
2026-08-24	Unavailable	Unavailable	2 / 1
2026-08-25	Unavailable	Unavailable	2 / 1
2026-08-26	Unavailable	Unavailable	2 / 1
2026-08-27	Unavailable	Unavailable	2 / 1
2026-08-28	Unavailable	Unavailable	2 / 1
2026-08-29	Unavailable	Unavailable	2 / 1
2026-08-30	Unavailable	Unavailable	2 / 1
2026-08-31	Unavailable	Unavailable	2 / 1
2026-09-01	Unavailable	Unavailable	2 / 1
2026-09-02	Unavailable	Unavailable	2 / 1
2026-09-03	Unavailable	Unavailable	2 / 1
2026-09-04	Unavailable	Unavailable	2 / 1
2026-09-05	Unavailable	Unavailable	2 / 1
2026-09-06	Unavailable	Unavailable	2 / 1
2026-09-07	Unavailable	Unavailable	2 / 1
2026-09-08	Unavailable	Unavailable	2 / 1
2026-09-09	Unavailable	Unavailable	2 / 1
2026-09-10	Unavailable	Unavailable	2 / 1
2026-09-11	Unavailable	Unavailable	2 / 1
2026-09-12	Unavailable	Unavailable	2 / 1
2026-09-13	Unavailable	Unavailable	2 / 1
2026-09-14	Unavailable	Unavailable	2 / 1
2026-09-15	Unavailable	Unavailable	2 / 1
2026-09-16	Unavailable	Unavailable	2 / 1
2026-09-17	Unavailable	Unavailable	2 / 1
2026-09-18	Unavailable	Unavailable	2 / 1
2026-09-19	Unavailable	Unavailable	2 / 1
2026-09-20	Unavailable	Unavailable	2 / 1
2026-09-21	Unavailable	Unavailable	2 / 1
2026-09-22	Unavailable	Unavailable	2 / 1
2026-09-23	Unavailable	Unavailable	2 / 1
2026-09-24	Unavailable	Unavailable	2 / 1
2026-09-25	Unavailable	Unavailable	2 / 1
2026-09-26	Unavailable	Unavailable	2 / 1
2026-09-27	Unavailable	Unavailable	2 / 1
2026-09-28	Unavailable	Unavailable	2 / 1
2026-09-29	Unavailable	Unavailable	2 / 1
2026-09-30	Unavailable	Unavailable	2 / 1
2026-10-01	Unavailable	Unavailable	2 / 1
2026-10-02	Unavailable	Unavailable	2 / 1
2026-10-03	Unavailable	Unavailable	2 / 1
2026-10-04	Unavailable	Unavailable	1 / 1
2026-10-05	Unavailable	Unavailable	1 / 1
2026-10-06	Unavailable	Unavailable	1 / 1
2026-10-07	Unavailable	Unavailable	1 / 1
2026-10-08	Unavailable	Unavailable	1 / 1
2026-10-09	Unavailable	Unavailable	1 / 1
2026-10-10	Unavailable	Unavailable	1 / 1
2026-10-11	Unavailable	Unavailable	1 / 1
2026-10-12	Unavailable	Unavailable	1 / 1
2026-10-13	Unavailable	Unavailable	1 / 1
2026-10-14	Unavailable	Unavailable	1 / 1
2026-10-15	Unavailable	Unavailable	1 / 1
2026-10-16	Unavailable	Unavailable	1 / 1
2026-10-17	Unavailable	Unavailable	1 / 1
2026-10-18	Unavailable	Unavailable	1 / 1
2026-10-19	Unavailable	Unavailable	1 / 1
2026-10-20	Unavailable	Unavailable	1 / 1
2026-10-21	Unavailable	Unavailable	1 / 1
2026-10-22	Unavailable	Unavailable	1 / 1
2026-10-23	Unavailable	Unavailable	1 / 1
2026-10-24	Unavailable	Unavailable	2 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	2	0	0
2026-06-01	2	0	0
2026-07-01	2	0	0
2026-08-01	2	0	0
2026-09-01	2	0	0
2026-10-01	2	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Advance ARDS Phase 2 and GVHD clinical data in 2026Direct metric needs a verified mapping
Reduce net losses toward -$2.74M by 2026-Q1Published status: Under Pressure
Improve operating income toward -$2.88M by 2026-Q1Operating income: $-3.217M

Next proof point

Nov 13, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-42.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

MiNK Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

INKT is a high-risk clinical-stage healthcare company, with its long-term case tied to progress in its programs rather than established earnings. Management has advanced clinical work and shown expense discipline, but the thesis remains in a watch state after a recent earnings miss.

What's priced into MiNK Therapeutics Inc

The evidence snapshot provides no valuation measure or specific account of market expectations, so it is not possible to judge whether the shares look cheap, fair, or expensive versus peers. Losses and high risk are clear, while the recent earnings miss has weighed on the thesis; confidence in this assessment is low.

What the fundamentals likely do

Near term, INKT is likely to keep reporting losses as it advances clinical programs, with recent net losses and declining cash showing the cost of that work. Management has reported positive initial Day 28 observations in its Phase 2 acute lung injury and ARDS trial and has improved losses over time, but cash use and a recent earnings miss remain risks.

What MiNK Therapeutics Inc hinges on

The multi-year thesis depends on clinical data, including ARDS and GVHD updates, and on management’s ability to fund that work while controlling expenses. Near term, a guidance cut or further weakening in jobs data could add pressure, while continued strength among healthcare sector bellwethers could support sector momentum.